Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical

Abstract

Background Clinical progression of Parkinson’s disease (PD) is highly heterogeneous, and its predictors are generally lacking. Identifying predictors of early disease progression is important for patients’ management and follow-up. The current study aims to identify clinical, neuroimaging and biochemical baseline predictors of motor progression in patients with PD. Forty-five PD patients were assessed at baseline, 6 months and 1 year using MDS-UPDRS total and subscores, Hoehn and Yahr (H&Y), Schwab and England (S&E), International Physical Activity Questionnaire (IPAQ). Baseline New Freezing of Gait Questionnaire (NFOG-Q), Berg Balance Scale (BBS), Ten-Meter Walking Test (10-MWT), and Time Up and Go Test (TUG), Non-Motor Symptoms Scale (NMSS), Beck Depression Inventory (BDI), PD questionnaire 39 (PDQ-39), MRI brain, uric acid, lipid profile and glycated hemoglobin were performed. Results Significant worsening of MDS-UPDRS total, part III scores, H&Y, S&E and IPAQ (p < 0.001) was detected. One-year progression of H&Y and S&E were significantly correlated to disease duration (p = 0.014, p = 0.025, respectively). Progression of H&Y was correlated to baseline TUG (p = 0.035). S&E progression was correlated to baseline MDS-UPDRS total score (rho = 0.478, p = 0.001) and part III (rho = 0.350, p = 0.020), H&Y (rho = 0.401, p = 0.007), PIGD (rho = 0.591, p < 0.001), NFOG-Q (rho = 0.498, p = 0.001), and TUG (rho = 0.565, p = 0.001). Using linear regression, there was no predictors of clinical progression among the used baseline variables. Conclusion Despite the significant motor and physical activity progression over 1 year that was correlated to baseline motor and gait severity, but without predictive value, further similar and longitudinal studies are warranted to detect predictors of early progression and confirm findings.

The p.Gly2019Ser is the commonest pathogenic mutation in the LRRK2 gene among Egyptians with familial and sporadic Parkinson's disease

“…An important observation in this study is that around one quarter of PD patients who did not have the p.Gly2019Ser mutation experienced symptoms before turning 50 years old. This percentage exceeds the global Early Onset Parkinson's Disease (EOPD) rates of 3-14% and aligns closely with data from previous clinical and epidemiological studies on EOPD in Egypt 23,35,36 . Interestingly, the incidence of a family history of PD was relatively low, around 16% in p.Gly2019Ser carriers and 11% in non-carriers.…”

Impact of Parkinson’s Disease on Functional Mobility at Different Stages

“…Previous studies had assessed the total time required to complete the Timed Up and Go (TUG) test and found that more advanced PD stages are associated with an increased time required to perform the test. However, these studies did not account for the HY stages and, therefore, our results are not entirely comparable (Schenkman et al, 2011;Helmy et al, 2022). Nonetheless, although this variable allows for differentiating the stages, clinical information regarding the physiological factors is missing.…”

Probiotic Supplementation in Parkinson’s Disease

“…However, due to the limited number of studies and inconsistency of results among current studies, no significant conclusions can be drawn. showing non significance due to limited number of studies and inconsistence result among current studies (Helmy et al, 2022). For a significant period of time, the Unified Parkinson's Disease Rating Scale (UPDRS) was the primary means of assessing the progression of PD.…”